Companies›Consumer Discretionary›Consumer Services›Retailing
NSE:ENTERO

ENTERO HEALTHCARE SOLU L

Consumer Services › Retailing·NIFTY MICROCAP 250NIFTY SMALLCAP 500NIFTY TOTAL MARKET
₹1,580.00
at close · 27 Oct 2026
▲ 108.90 (+7.40%)

Latest filings

Next results: Wed, 4 Nov · Financial Results/Other business matters
  1. Board to review September quarter results on November 4 · Results
  2. Routine quarterly RTA certificate under SEBI Depositories Regulations · Compliance
  3. Allotment of 43,155 equity shares under ESOP 2023 to eligible employees · Capital Market Events
All filings ↓
Ask Nexa about ENTERO HEALTHCARE SOLU L

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Distributes pharmaceutical and healthcare products to a retail network of more than 105,300 pharmacies and 3,600 hospitals, supported by 136 warehouses, 137 offices and 48 subsidiaries spread across 21 states and 523 districts. In FY26, the business reported revenue of Rs 6,591 crore, up 29.3% year-on-year with 31.5% like-for-like growth, while EBITDA rose 55% to Rs 266 crore at a 4.0% margin. Growth has come from a mix of like-for-like expansion and acquisitions — seven acquisitions were completed during the year, including a 51.51% stake in Anand Chemiceutics. A MedTech line has scaled to annualized revenue exceeding Rs 1,000 crore, and the company employs about 4,970 staff. Stated operating cost items are employee costs at 3.7% of revenue, other operating expenses at 2.6% and depreciation at 0.7%, with capex at 1.0% of revenue. Operating cash flow turned positive at Rs 96 crore in FY26, although Q4 FY26 absorbed Rs 114 million in one-off items including business contract closure expenses and write-offs.

Operating scale
Pharmacy customers
105,300+FY26
Hospital customers
3,600+FY26
Warehouses
136FY26
Districts covered
523FY26
Employees
~4,970FY26
MedTech annualized revenue
>Rs 1,000 croreFY26
Who pays it
Retail pharmacies, hospitals and other healthcare buyers across 21 states
Biggest cost
Employee costs at 3.7% of revenue and other operating expenses at 2.6% are the largest stated cost items; depreciation is 0.7% of revenue
Kind of business
Asset-light, low-margin pharmaceutical distribution with acquisition-led growth
Where it sits
Wide distribution network covering 105,300+ pharmacies and 3,600+ hospitals across 21 states and 523 districts
Market Cap
₹6,877 Cr
P / E (TTM)
54.8×
EV / EBITDA
22.7×
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
11.6%·
ROCE (FY26)
ROE 8.3% · margin 4.2%
Leverage
0.32·
Debt / Equity · low
Net debt ₹420 Cr
Revenue FY24→FY26
1.7×▲
Margin +1.2 pts
₹3,922 Cr → ₹6,591 Cr
Cash conversion
-0.06×▼
Operating cash ÷ profit · 3 yrs
₹-17 Cr on ₹293 Cr
Moves on a normal day
1.34%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 65 Retailing peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#43/52
P/B#30/50
ROCE#25/63
ROE#23/49
Debt / Equity#38/49
EBITDA margin#36/50
Revenue growth#12/51
Profit growth#10/46

Scorecard

Measured from the filed financials, judged against its Retailing peers · as of FY26 — not investment advice

Strengths
Returns on capital 11.6%
#25 of 63 in Retailing on the latest reported figures
Concerns
Carries more debt than its peers — 0.32× equity
higher than 77% of its 49 Retailing peers
Over 3 years it reported ₹293 Cr of profit and an operating cash outflow of ₹17 Cr — -0.06×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ENTERO HEALTHCARE SOLU L's filed financials and exchange disclosures

What does ENTERO HEALTHCARE SOLU L do?

ENTERO HEALTHCARE SOLU L is a Retailing company listed on NSE and BSE, trading under the symbol ENTERO.

Is ENTERO HEALTHCARE SOLU L profitable?

Yes. Over the trailing twelve months ENTERO HEALTHCARE SOLU L reported a net profit of ₹168 Cr on revenue of ₹7,128 Cr.

Does ENTERO HEALTHCARE SOLU L pay a dividend?

Not in the latest reported year — ENTERO HEALTHCARE SOLU L's dividend payout for FY26 was nil.

Is ENTERO HEALTHCARE SOLU L debt-free?

No. It reported borrowings of ₹567 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹420 Cr after cash. Debt stands at 0.32× equity. That is higher than 77% of its 49 Retailing peers.

Is ENTERO HEALTHCARE SOLU L expensive compared with its peers?

On trailing P/E, ENTERO HEALTHCARE SOLU L ranks 43 of 52 in Retailing — cheaper than 18% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.

How much does the ENTERO HEALTHCARE SOLU L share price move in a day?

On a typical session ENTERO HEALTHCARE SOLU L moves 1.34% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

When are ENTERO HEALTHCARE SOLU L's next results?

Financial Results/Other business matters on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track ENTERO HEALTHCARE SOLU L's announcements?

Every NSE and BSE filing by ENTERO HEALTHCARE SOLU L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.